跳至主要内容
临床试验/IRCT138706051100N1
IRCT138706051100N1已完成2 期

?Evaluation of therapeutic efficacy of treatment with olanzapine and halopridol on regional cerebral blood flow measured by SPECT in patients with schizophrenia, correlating with the response to treatment

Deputy of Research, Tehran University of Medical Sciences0 个研究点目标入组 28 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
28

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 58 years(—)
性别
All

入选标准

  • the criteria of DSM-IV for schizopherenia; neuroleptic drug-naive or drug-free for at least 4 weeks; age range from 18-58 years; filling consent form; no drug tranqulization for at least five half life of the drug; no psychoactive drug therapy for at least 5 half life of the drug. Exclusion criteria: Accompanied disorders of axis 1 or 2 based on DSM-IV; evidence of neurological disease; History of any drug abuse; elevating hepatic enzymes; pregnancy; thyroid dysfunction; consumption of drugs interferring with HT25 or D2 receptors.

排除标准

  • 未提供

研究者

发起方
Deputy of Research, Tehran University of Medical Sciences

相似试验